Reglagene
Oro Valley, US · Founded 2018 · 1 known investors
Reglagene is developing an orally administered, small-molecule tubulin-targeting therapy that crosses the blood-brain barrier to treat brain cancers. The company targets brain tumors where standard-of-care treatments fall short, positioning its low-molecular-weight drug for central nervous system penetration.
Founders & leadership
RA
Richard AustininNamed on SEC filing
LH
Laurence HurleyNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$5.7M disclosed across 4 rounds · 2018–2024
▶$766.7KraisedMay 2024 · 12 investors · BiotechnologyRule 506(b)
▶$766.7KraisedMay 2024 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard AustinExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $766.7K
- Minimum investment
- $50K
- First sale
- May 2024
- Incorporated
- Corporation, Arizona, 2024
- Federal exemptions
- 06b
▶$3.8MraisedNov 2023 · 22 investors · BiotechnologyRule 506(b)
▶$3.8MraisedNov 2023 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sharon AydDirector
- Lawrence KinetDirector
- Laurence HurleyDirector
- Richard AustinExecutive Officer, Director
- Offering amount
- $3.8M
- Amount sold
- $3.8M
- Minimum investment
- $25K
- First sale
- Jul 2022
- Incorporated
- Corporation, Arizona, 2018
- Federal exemptions
- 06b
▶$600KraisedJul 2021 · 3 investors · BiotechnologyRule 506(b)
▶$600KraisedJul 2021 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sharon AydDirector
- Laurence HurleyDirector
- Lawrence KinetDirector
- Richard AustinExecutive Officer, Director
- David J. BearssDirector
- Offering amount
- $1.5M
- Amount sold
- $600K
- Minimum investment
- $25K
- First sale
- Jul 2021
- Incorporated
- Corporation, Arizona, 2018
- Federal exemptions
- 06b
▶$546.4KraisedAug 2018 · 11 investors · BiotechnologyRule 506(b)
▶$546.4KraisedAug 2018 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard AustinExecutive Officer, Director
- Laurence HurleyDirector
- Offering amount
- $2M
- Amount sold
- $546.4K
- Minimum investment
- $25K
- First sale
- Jul 2018
- Incorporated
- Corporation, Arizona, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Reglagene do?
- Reglagene is developing an orally administered, small-molecule tubulin-targeting therapy that crosses the blood-brain barrier to treat brain cancers. The company targets brain tumors where standard-of-care treatments fall short, positioning its low-molecular-weight drug for central nervous system penetration.
- Who are Reglagene's investors?
- Reglagene's investors include Cancer Fund.
- How much funding has Reglagene raised?
- Reglagene has disclosed $5.7M raised across 4 rounds.
- Where is Reglagene headquartered?
- Reglagene is headquartered in Oro Valley, US.